×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:NVCR

NovoCure (NVCR) Stock Forecast, Price & News

$80.19
+4.60 (+6.09%)
(As of 05/26/2022 04:00 PM ET)
Add
Compare
Today's Range
$74.95
$80.69
50-Day Range
$57.94
$89.90
52-Week Range
$56.51
$232.76
Volume
523,476 shs
Average Volume
659,115 shs
Market Capitalization
$8.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.88
30 days | 90 days | 365 days | Advanced Chart
Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NovoCure logo

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,167
Year Founded
N/A

Sales & Book Value

Annual Sales
$535.03 million
Book Value
$4.17 per share

Profitability

Net Income
$-58.35 million
Pretax Margin
-9.64%

Debt

Price-To-Earnings

Miscellaneous

Free Float
99,283,000
Market Cap
$8.39 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/26/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.05 out of 5 stars

Medical Sector

523rd out of 1,424 stocks

Surgical & Medical Instruments Industry

61st out of 137 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -













NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NovoCure stock.
View analyst ratings for NovoCure
or view top-rated stocks.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for NovoCure
.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, April, 28th. The medical equipment provider reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.15. The medical equipment provider had revenue of $137.50 million for the quarter, compared to analyst estimates of $134.29 million. NovoCure had a negative trailing twelve-month return on equity of 14.21% and a negative net margin of 10.94%. The company's revenue for the quarter was up 2.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.04) earnings per share.
View NovoCure's earnings history
.

What price target have analysts set for NVCR?

8 Wall Street analysts have issued 1-year price objectives for NovoCure's shares. Their forecasts range from $70.00 to $250.00. On average, they anticipate NovoCure's share price to reach $144.75 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for NovoCure
or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?
NovoCure's management team includes the following people:
What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different retail and institutional investors. Top institutional investors include Capital World Investors (12.10%), Capital International Investors (10.85%), Baillie Gifford & Co. (8.93%), Vanguard Group Inc. (7.65%), BlackRock Inc. (6.44%) and Deep Track Capital LP (0.96%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure
.

Which institutional investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Compagnie Lombard Odier SCmA, Zurcher Kantonalbank Zurich Cantonalbank , KBC Group NV, Baillie Gifford & Co., Banque Pictet & Cie SA, Citigroup Inc., and Russell Investments Group Ltd.. Company insiders that have sold NovoCure company stock in the last year include Ashley Cordova, Ely Benaim, Frank X Leonard, Gabriel Leung, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which institutional investors are buying NovoCure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including Deep Track Capital LP, Sumitomo Mitsui Trust Holdings Inc., Wolverine Asset Management LLC, Vanguard Group Inc., JPMorgan Chase & Co., Clearbridge Investments LLC, Frontier Capital Management Co. LLC, and C WorldWide Group Holding A S.
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $80.19.

How much money does NovoCure make?

NovoCure has a market capitalization of $8.39 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58.35 million in net income (profit) each year or ($0.560010) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,167 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 441534756700 or via email at [email protected].

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.